List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 39 studies with search of: "Vatalanib"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
Condition: Sarcoma
Intervention: Drug: PTK787/ZK222584
2 Active, not recruiting Trial of PTK787/ZK 222584 Plus Paclitaxel
Condition: Metastatic Non-Hematologic Malignancies
Interventions: Drug: PTK787/ZK 222584;   Drug: paclitaxel
3 Terminated PTK787 in Refractory or Relapsed Diffuse Large Cell Lymphoma
Condition: Lymphoma, Large-Cell, Diffuse
Intervention: Drug: PTK787/ZK 222584
4 Completed Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Effects of Vatalanib in Combination With Capecitabine in Patients With Advanced Cancer
Conditions: Tumors;   Neoplasm Metastasis
Intervention: Drug: PTK787/ZK 222584 (vatalanib)
5 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
6 Completed Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
Conditions: Colorectal Neoplasms;   Colonic Neoplasms;   Rectal Neoplasms
Intervention: Drug: Vatalanib
7 Completed PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
Conditions: Refractory Malignancy;   Advanced Malignancies
Intervention: Drug: PTK787/ZK222584 and Bevacizumab
8 Completed Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
Condition: Wet Age-Related Macular Degeneration
Interventions: Drug: PTK787;   Drug: PTK787;   Drug: Placebo
9 Recruiting Safety and Efficacy Study of PTK787/ZK222584 to Treat Metastatic Neuroendocrine Tumors
Condition: Metastatic Neuroendocrine Tumors
Intervention: Drug: vatalanib
10 Completed PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP
Conditions: Acute Myelogenous Leukemia;   Agnogenic Myeloid Metaplasia;   Chronic Myelogenous Leukemia
Interventions: Drug: imatinib mesylate (Gleevec);   Drug: PTK 787 (vatalanib)
11 Completed Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Conditions: Von Hippel-Lindau Disease;   CNS Hemangioblastoma;   Retinal Hemangioblastoma
Intervention: Drug: PTK787/ZK 222584
12 Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: PTK787/ZK 222584;   Drug: Gemcitabine
13 Active, not recruiting Study of PTK787 in the Treatment of Patients With Non-Metastatic Androgen Independent Prostate Cancer
Condition: Prostate Cancer
Intervention: Drug: PTK787/ZK 222584
14 Active, not recruiting Imatinib and PTK787/ZK222584 in Refractory and/or Advanced Solid Tumors
Conditions: Refractory Malignancy;   Solid Tumors
Intervention: Drug: Imatinib and PTK/ZK222584
15 Recruiting PTK787/ZK 222584 in Combination With Temozolomide and Radiation in Patients With Glioblastoma Taking Enzyme-Inducing Anti-Epileptic Drugs
Condition: Glioblastoma
Interventions: Drug: PTK787/ZK 222584;   Drug: Temozolomide;   Procedure: Radiation Therapy
16 Active, not recruiting PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: vatalanib
17 Completed PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
Condition: Neoplasm
Intervention: Drug: PTK787/ZK222584
18 Active, not recruiting Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Conditions: Kidney Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib
19 Active, not recruiting Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Intervention: Drug: vatalanib
20 Recruiting Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Head and Neck Cancer;   Islet Cell Tumor;   Kidney Cancer;   Lung Cancer;   Melanoma (Skin);   Neuroendocrine Carcinoma of the Skin;   Pheochromocytoma;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: everolimus;   Drug: vatalanib;   Genetic: protein expression analysis;   Other: high performance liquid chromatography;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Procedure: ultrasound imaging

Previous Page Studies Shown (1-20) Next Page (21-39)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services